Claims

1. Use of an epithelial cell growth factor receptor (EGFR) inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), wherein the aforementioned EGFR inhibitor is a PDGF Receptor Tyrosine Kinase Inhibitor III or BPIQ-I.

2. Use of a fibroblast growth factor receptor (FGFR) inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), wherein the aforementioned FGFR inhibitor is Pazopanib or an analog thereof or PDGF Receptor Tyrosine Kinase Inhibitor III.

3. The use according to claim 2, wherein the ALS is ALS having mutation in TDP-43 gene and/or C9orf72 gene.

4. Use of an Aurorakinase inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene, wherein the aforementioned Aurorakinase inhibitor is ZM-447439, VX-680, Aurora Kinase Inhibitor II, CYC116, KW2449, or AT9283.

5. Use of a protein kinase A (PKA) inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), wherein the aforementioned PKA inhibitor is PDGF Receptor Tyrosine Kinase Inhibitor III.

6. Use of a PKC inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene, wherein the aforementioned PKC inhibitor is PDGF Receptor Tyrosine Kinase inhibitor III or Enzastaurin.

7. Use of an MEK inhibitor in the manufacture of a prophylactic

and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), wherein the aforementioned MEK inhibitor is U0126-EtOH.

8. Use of a Met inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 dene, wherein the aforementioned Met inhibitor is MGCD-265, PF-2341066 (Crizotinib) or an analog thereof or BMS 777607.

9. Use of a JNK inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene, wherein the aforementioned JNK inhibitor is SP600125.

10. Use of a Syk inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), wherein the aforementioned Syk inhibitor is a Syk Inhibitor.

11. Use of JAK inhibitor in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene, wherein the aforementioned JAK inhibitor is JAK Inhibitor I or AT9283.

12. Use of a prostaglandin analogue in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene, wherein the aforementioned prostaglandin analogue is Bimatoprost.

13. Use of an estrogen receptor antagonist in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS), wherein the aforementioned estrogen receptor antagonist is Raloxifene.

14. Use of Tivozanib in the manufacture of a prophylactic

and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene and/or TDP-43 gene and sporadic ALS.

15. Use of Bosutinib (SKI-606) or Sunitinib in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene and/or C9orf72 gene and sporadic ALS.

16. Use of Nilotinib in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in SOD1 gene.

17. Use of Axitinib in the manufacture of a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis (ALS) having mutation in C9orf72 gene.